Previous Article | Next Article 
Journal of Clinical Microbiology, March 2000, p. 1066-1071, Vol. 38, No. 3
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Simultaneous Detection of Multiplex-Amplified Human
Immunodeficiency Virus Type 1 RNA, Hepatitis C Virus RNA, and Hepatitis
B Virus DNA Using a Flow Cytometer Microsphere-Based
Hybridization Assay
J.-P.
Defoort,*
M.
Martin,
B.
Casano,
S.
Prato,
C.
Camilla, and
V.
Fert
Immunoanalysis Department, Immunotech, a
Beckman-Coulter Company, 13276 Marseille Cedex 9, France
Received 13 May 1999/Returned for modification 26 August
1999/Accepted 26 November 1999
 |
ABSTRACT |
The feasibility of performing a multiplex assay for the detection
of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus
(HCV) RNAs and hepatitis B virus (HBV) DNA is demonstrated. This assay
is based (i) on the coamplification of a 142-bp fragment from the
gag region of the HIV-1 genome and a 142-bp HIV-1
quantitation standard fragment, a 244-bp fragment from the 5' noncoding
region of the HCV genome, and a 104-bp fragment from the pre-C and C gene regions of the HBV genome, using three sets of specific primers; (ii) on the capacity of these four biotinylated PCR products to hybridize to their specific oligonucleotide probe-coated microspheres; and (iii) on the ability of the flow cytometer to discriminate between
distinct fluorescent-microsphere categories. Absence of cross-hybridization between the unrelated oligonucleotide probes and
PCR products generated by the multiplex reverse transcription-PCR (RT-PCR) and the highly sensitive detection method allowed us to assess
unambiguously the HIV-1 viral load and the infectious status of 35 serologically well-established clinical samples and 20 seronegative
blood donor plasma samples tested. The results indicate that multiplex
RT-PCR and flow cytometer microsphere-based hybridization assays, when
combined, provide a rapid, sensitive, and specific method for the
quantitation and detection of the major viral agents of infectious
diseases in a single plasma sample.
 |
INTRODUCTION |
The development of nucleic acid
amplification technologies has found many applications in biomedical
research and in diagnostic techniques. The study of infectious diseases
is a field that has benefited much from these technologies.
Amplification of up to several millionfold of low-copy-number DNA or
RNA allows one to make an early and rapid diagnosis of bacterial or
viral infections (6, 7, 18, 20). Moreover, techniques for
the quantitation of the viral load in plasma have been shown to be of
particular interest in monitoring drug therapy and in predicting the
disease outcome (12, 15). For several years, attempts have
been made to use multiplex PCR or reverse transcription-PCR (RT-PCR) in order to detect several different pathogens or serotypes in coinfected samples after a single reaction (10, 19). In such assays, primer pairs are chosen with respect to their compatibility and ability
to simultaneously amplify their specific target sequences. Detection of
amplified products is usually done by gel electrophoresis, which
discriminates fragments of distinct sizes by ethidium bromide staining
or by hybridization using specific DNA probes. Even though multiplex
RT-PCR simplifies the procedures, analysis remains tedious and
labor-intensive. The development of solid phase hybridization assays
greatly improved the practicability of these assays and allowed the
detection of different PCR products from one multiplex PCR
amplification run (1, 3). Usually, each specific amplified product is detected in a separate well. The amplicon volume becomes a
limiting factor. To address this problem, we describe here the use of a
flow cytometer and a microsphere-based hybridization assay for the
detection of multiplex RT-PCR products in a single tube. This assay
relies on the ability of the flow cytometer to resolve multiple
microsphere-based assays (5). The red fluorescence intensity
(675 nm) emitted by an oligonucleotide probe-coated microsphere
population results from the hybridization of its target PCR-amplified
sequence with the specific oligonucleotide probe. The simultaneous
detection of different target sequences is achieved by mixing several
specific oligonucleotide probe-coated microsphere populations, which
are differentiated by their level of green fluorescence intensity (525 nm). We demonstrate, using human immunodeficiency virus type 1 (HIV-1),
hepatitis C virus (HCV), and hepatitis B virus (HBV) as models, that
multiplex RT-PCR and microsphere-based flow cytometric assays
constitute an accurate, specific, and rapid method for the simultaneous
detection and quantitation of several different viruses in one plasma sample.
 |
MATERIALS AND METHODS |
Oligonucleotide primers and probes and thiol-reactive
microspheres.
Primers for the amplification of the HIV-1, HCV, and
HBV genomes and probes for the specific detection of PCR products are presented in Table 1. These sets of
primers were derived from the HIV-1 gag gene
(14), the HCV 5' noncoding region (22, 23), and
the pre-C and C regions of the HBV genome (9), respectively. Antisense (SK431) and sense (SK462) primers for HIV-1 and antisense primers for HCV (KY78) and HBV (PB1) were biotinylated at the 5' ends
to allow detection of the amplified products. Oligonucleotide capture
probes were modified at the 5' ends with a thiol linker to allow their
covalent coupling to Immunotech-Coulter 3.7-µm-diameter thiol-reactive microspheres. SK102 and CP35 are oligonucleotide probes
for HIV-1 detection. They are specific for the detection of amplified
HIV-1 RNA and the quantitation standard, respectively. Oligonucleotides
KY150 and PB3 allowed detection of amplified HCV RNA and HBV DNA,
respectively. Modified 5'-end-biotinylated oligonucleotides
complementary to SK102, KY150, and PB3 were synthesized to evaluate the
sensitivity of detection.
Four distinct intensity levels of green-fluorescent (525 nm)
3.7-µm-diameter thiol-reactive microspheres were used (Fig.
1).
SK102, coding for the HIV-1 RNA, was
applied to the dimmest green-fluorescent
microspheres. CP35, coding for
the HIV-1 quantitation standard,
was applied to the
second-level-intensity microspheres. KY150,
coding for the HCV RNA, was
applied to the third-level-intensity
microspheres, and PB3, coding for
the HBV DNA, was applied to
the brightest microspheres.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Typical dot plots of green fluorescence versus red
fluorescence for the mixture of the four oligonucleotide-coated
microsphere populations for the simultaneous detection of RT-PCR
products from HIV-1, HCV, and HBV nucleic acids.
|
|
Clinical samples, preparation, and amplification.
Fifty-five
plasma samples were tested. These samples represented five groups:
group 1, HCV infection only (n = 13); group 2, HIV-1
infection only (n = 8); group 3, concurrent HIV-1 and HCV infection (n = 12); group 4, concurrent HIV-1 and
HBV infection (n = 2); and group 5, seronegative blood
donors (n = 20). All plasma samples were kept at
20°C after collection. Extraction of genomic RNA and DNA from these
55 plasma samples was achieved with the AMPLICOR HIV-1 MONITOR Test
(reference no. 07 5623 7) according to the recommendations of the
manufacturer (Roche). The only difference was in the volume of plasma
extracted (100 µl). The extracted RNA and DNA were dissolved in 200 µl of diluent buffer, aliquoted in Safe Lock 0.5-ml Eppendorf tubes
for PCR, and stored frozen at
20°C prior to amplification. HIV-1
RT-PCR was done by mixing 25 µl of extract and 25 µl of Working
Master Mix from the AMPLICOR HIV-1 MONITOR Test to amplify HIV-1 RNA only. Multiplex RT-PCR was done by mixing 25 µl of extract and 25 µl of Working Master Mix from the AMPLICOR HIV-1 MONITOR Test, to
which 5 pmol each of the HCV and HBV primers had been added in order to
simultaneously amplify HIV-1 and HCV RNAs and HBV DNA. Amplification
was carried out in a single tube in a Biometra Trio Thermoblock with a
heated lid. Following 2 min of incubation at 50°C, reverse
transcription was allowed to proceed for 30 min at 60°C. After a
denaturation step at 95°C, PCR amplification was then carried out
with four cycles of 95, 55, and 72°C for 30 s each, followed by
26 cycles of 90, 60, and 72°C for 30 s each. After the last
cycle, the temperature was maintained at 72°C while 50 µl of
denaturation solution was added to each PCR tube. The RT-PCR-amplified
products are referred to as the amplicon.
Flow cytometer microsphere-based hybridization assay.
The
simultaneous detection of RT-PCR products was achieved with a flow
cytometer microsphere-based hybridization assay. Briefly, 100 µl of a
fivefold dilution of denatured amplicon in a hybridization buffer
containing 1.2 M NaCl, 0.2 M phosphate (pH 6), 5 mM EDTA, 0.05% Tween
20, 10 mM NaN3, and 5 g of bovine serum albumin per liter was incubated with 10 µl of a microsphere mixture containing 10,000 probe-coated microspheres from each of the four microsphere categories (SK102, CP35, KY150, and PB3) in a Loprodine
0.45-µm-pore-size membrane-bottomed 96-microwell plate (Nunc).
Hybridization of RT-PCR products to their cognate probe-coated
microspheres was carried out for 90 min with shaking at 37°C. The
microplate was then placed on a vacuum manifold to allow five washing
cycles with 250 µl of wash solution. Detection of bound biotinylated RT-PCR product to probe-coated microspheres was then done by incubating 100 µl of streptavidin-phycoerythrin cyanin 5 conjugate (Immunotech) for 30 min with shaking at 37°C. Unbound streptavidin-phycoerythrin cyanin 5 conjugate was removed with two more washes, and the
microspheres were resuspended in 300 µl of 10 mM phosphate buffer (pH
7) containing 150 mM NaCl, 10 mM NaN3, and 5 g of bovine serum
albumin per liter and transferred to a flow cytometer tube. Finally,
the microspheres were analyzed on an EPICS-XL MCL flow cytometer
(Beckman-Coulter).
Data acquisition and data processing.
Data acquisition was
performed at high speed until a minimum of 2,000 microspheres had been
acquired. Once each individual microsphere has been analyzed for its
green (525-nm) and red (675-nm) fluorescence intensities, software
designed in-house computes the data and attributes to each microsphere
population a mean red fluorescence intensity value. This value is
related directly to the amount of biotinylated RT-PCR product
hybridized with the oligonucleotide probe on the microspheres.
Nucleotide sequence accession numbers.
The GenBank accession
numbers for the viral sequences are as follows: HCV, D90208; HBV,
X02496; and HIV-1, K02083.
 |
RESULTS |
Analytical sensitivity of the detection system.
The analytical
sensitivity of the flow cytometer microsphere-based hybridization assay
for the detection of nucleic acids was studied with biotinylated
oligonucleotides complementary to the SK102, KY150, and PB3
oligonucleotide probe-coated microspheres. Serial dilutions of the
biotinylated oligonucleotides, specific for HIV-1 and HCV RNAs and HBV
DNA, respectively, were assayed by the protocol described in Materials
and Methods. The sensitivities found were within a range of 6 to 20 fmol/liter (0.4 × 106 to 1.2 × 106
molecules/100 µl) (data not shown). The small difference observed between these oligonucleotides is not surprising, since it is well
known that the hybridization behavior of short oligonucleotides is very
dependent on their respective sequences and secondary structures. The
microwell plate provided in the AMPLICOR HIV-1 MONITOR Test for HIV-1
RNA RT-PCR product detection gives similar sensitivity (data not shown).
Multiplex RT-PCR combined with microsphere-based hybridization
assay.
It is essential to exclude cross-hybridization between
oligonucleotide probe-coated microspheres and unrelated RNA amplified by RT-PCR in any assessment of the infectious status of a plasma sample. Using monoamplified RT-PCR plasma samples with a high virus
load, we showed that the three amplified fragments for HIV-1, HCV, and
HBV hybridized specifically to their cognate oligonucleotide probes.
When these amplicons were assayed, using the three HIV-1-, HCV-, and
HBV-specific microsphere categories, a high red fluorescence intensity
was obtained only with the relevant microsphere category. The signals
measured with the unrelated microspheres were lower than the cutoff
values calculated from the analysis of 20 seronegative blood donor
plasma samples (Table 2). The cutoff
values were calculated as the means of the values plus 5 standard
deviations; the means and standard deviations, respectively, were 0.75 and 0.34 for SK102 (HIV-1), 0.49 and 0.11 for KY150 (HCV), and 0.44 and
0.13 for PB3 (HBV). Since the CP35 microsphere codes for the HIV-1
quantitation standard, no cutoff value was calculated. A high
fluorescence intensity level for this category of microspheres validates both the RT-PCR amplification and the hybridization steps.
The analysis of the clinical samples from groups 1 to 4 was performed
as follow. A specimen was considered positive for a
given virus when
the signal was higher than the cutoff value for
the particular
microsphere category. In Table
3 are
presented
the raw data obtained from these 35 samples. HCV RNA was
detected
in all of the HCV-positive samples (25 of 25). HIV-1 RNA was
detected
in all specimens from groups 2 (8 of 8) and 4 (2 of 2) and in
11 of 12 specimens from group 3. The two specimens from group
4 were
shown to be positive for HBV. The four dot plots presented
in Fig.
2 summarize how, after two simple steps,
it is possible
to assess unambiguously the viral status of a plasma
sample.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Detection of HIV-1, HCV, and HBV viremia in plasma
samples from 35 seropositive subjects by multiplex RT-PCR and one-tube
flow cytometer microsphere-based hybridization assays
|
|

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
Typical dot plots of green fluorescence versus red
fluorescence for virus-free or seropositive plasma samples. (A)
Virus-free plasma sample; (B) HIV-1-seropositive plasma sample; (C)
HIV-1- and HBV-seropositive plasma sample; (D) HCV-seropositive plasma
sample.
|
|
HIV-1 RNA multiplex versus monoplex quantitation.
Quantitation
of HIV-1 RNA using the flow cytometer microsphere-based hybridization
assay can be performed readily, since both microspheres, i.e., those
specific for HIV-1 RNA and the quantitation standard, are incubated
simultaneously. The number of HIV-1 RNA copies per milliliter was
calculated as the ratio of the red fluorescence intensities for HIV-1
RNA (SK102) and the quantitation standard (CP35) from the same assay
times a constant value which takes into account the dilutions of the
overall extraction procedure and the input number of quantitation
standard copies per PCR. Quantitation of the HIV-1 RNA viral load from
21 specimens (8 positive for HIV-1 only, 11 positive for HIV-1 and HCV,
and 2 positive for HIV-1 and HBV) was carried out after multiplex or monoplex RT-PCR amplification and microsphere-based hybridization assay. As shown in Fig. 3, the
quantitation values for HIV-1 RNA from HIV-1 RT-PCR correlated well
with those obtained by multiplex RT-PCR (r = 0.956).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of HIV-1 RNA viral loads (copies per
milliliter from 21 specimens after HIV-1 RT-PCR (x axis) and
multiplex RT-PCR (y axis). Linear regression was calculated
as follows: log (HIV-1 RT-PCR) = 1.07 log (multiplex RT-PCR) 0.37; r = 0.956.
|
|
 |
DISCUSSION |
In view of the increasing number of multiple infections in
patients and the interest in domains as different as blood banking and
disease control, it has become important to find techniques for
optimizing the screening of large numbers of samples. The use of
the flow cytometer as a tool in microsphere-based fluorimetric assays
is a concept that was first described in the 1970s (5). Taking advantage of the ability of the flow cytometer to resolve complex mixtures of microspheres on the basis of size and level of
fluorescence, it was shown that this technology was applicable for the
simultaneous detection of antibodies specific for different antigens
and for the measurement of several soluble antigens in a
microsphere-based assay (4, 16). Later, it was reported that
this methodology could also be adapted for the detection of
PCR-amplified nucleic acid sequences (17, 21). However, none
of these studies demonstrated the simultaneous use of multiplex RT-PCR
and the microsphere-based hybridization assay. They showed only the
detection of a monospecific amplified viral DNA or RNA in a single
(21) or multiple (17) microsphere-based
hybridization assays.
In this study, we investigated the possibility of combining multiplex
RT-PCR amplification and flow cytometer microsphere-based hybridization
assays in order to improve screening methods for RT-PCR-based virus
detection. As a model, we developed an assay for the simultaneous
amplification and detection of HIV-1, HCV, and HBV.
The multiplex RT-PCR amplification of genomic sequences from three
different viruses requires the use of three pairs of primers to amplify
each viral nucleic acid with a high yield. The primers we used in this
study have been described previously (9, 14, 23). They allow
the amplification of a 142-bp fragment from the gag region
of HIV-1, a 244-bp fragment from the 5' noncoding region of the HCV
genome, and a 104-bp fragment from the pre-C and C gene regions of HBV.
The optimization of the multiplex RT-PCR amplification was focused
first on the compatibility of these primers during RT-PCR
amplification. Only one minor modification of the antisense
primer for HBV (9) was necessary. This primer and the KY78 primer
for HCV generated a primer-specific by-product during the RT-PCR
amplification step that induced unexpectedly high nonspecific binding
to the HIV-1 RNA detection microsphere (SK102-coated microsphere) (data
not shown). This nonspecific binding was reduced to background noise
when the PB1 primer (antisense primer with the 3' end deleted) was
used. Second, primer compatibility for multiplex RT-PCR amplification
was demonstrated after analysis of the amplicons obtained from 20 seronegative blood donor plasma samples. Finally, we showed that
amplification efficiency was not affected by the simultaneous use of
these three pairs of primers. Indeed, the calculated HIV-1 viral load
from HIV-1-containing specimens after HIV-1 RT-PCR correlates well with
the HIV-1 viral load calculated from the same specimens after the
multiplex RT-PCR. These results indicate that the amplification yields
of the HIV-1 RNA and the internal standard for the HIV-1 RNA
quantitation were similar. More interestingly, we also found also a
good correlation for HIV-1 viral load for plasma samples coinfected
with HIV-1 and HCV or HBV viruses which were subjected to HIV-1 RT-PCR
or multiplex RT-PCR amplification.
Detection of each of the RT-PCR-amplified nucleic acids was achieved in
a microsphere-based hybridization assay. Two oligonucleotide capture
probes were used for the quantitation of the HIV-1 viral load. SK102
was specific for the detection of the HIV-1 RNA. CP35 was specific for
the detection of the quantitation standard, an RNA transcript that is
amplified using the same primers as those for the HIV-1 RNA but that
contains a specific probe binding region that allows the quantitation
standard to be distinguished from the HIV-1 RNA PCR product. Two other
specific oligonucleotide capture probes were used for the detection of
HBV and HCV. These four oligonucleotide capture probes were coupled to
four distinct green-fluorescent microsphere categories. We showed in
cross-hybridization experiments that these four
oligonucleotide-coated microsphere categories could be used
together in the same assay. HIV-1-, HCV-, and HBV-amplified nucleic
acid products hybridized specifically to their cognate oligonucleotide
capture probe microsphere. No significant hybridization of the RT-PCR
products to irrelevant microspheres could be observed. This finding was
further confirmed with the analysis of monoinfected plasma samples.
None of these samples was found positive for a second viral infection
when the fluorescence intensity measured was compared to the cutoff values.
The validation of this approach using two very sensitive methods, i.e.,
RT-PCR amplification, which increases small quantities of nucleic acid
several millionfold, and flow cytometer microsphere-based hybridization
assays, which can detect as few as
0.4 × 106
biotinylated target molecules per assay, was achieved by investigating a total of 55 plasma samples. Twenty of them, obtained from
seronegative blood donors, were analyzed to calculate cutoff values in
order to classify samples as positive or negative. The analysis of the remaining 35 serologically characterized clinical plasma samples showed
almost perfect correlation with the expected status. Concordance was
perfect with the exception of one HIV-1-positive sample in group 3 (sample 6) which was found negative in this study. An aliquot of the
same extract amplified only for HIV-1 was also found to be negative for
HIV-1 when assayed with the Roche kit. This result indicates that the
presence of a high copy number of the HCV genome, demonstrated by the
high fluorescence signal measured in the KY150 (HCV) microsphere
population, did not hamper amplification of the HIV-1 genome of this sample.
In conclusion, the use of multiplex RT-PCR and a flow cytometer
microsphere-based hybridization assay greatly simplified the overall
procedures for the detection of several viral pathogens. These data
demonstrate that, using these two techniques in combination, it is
possible to assess unambiguously and with great sensitivity the
infectious status of plasma samples for at least three infectious viruses. One would expect that the simultaneous amplification and
detection of more than three nucleic acid sequences could be done using
the appropriate primer pairs and oligonucleotide capture probes.
 |
ACKNOWLEDGMENTS |
This work was fully supported by Immunotech, a Beckman Coulter company.
We thank particularly J. Fieschi and E. Rouvier for helpful discussions
and advice, E. Lagier (Hopital d'Aix en Provence) for providing us
with clinical specimens, J. Quintana for providing us with the
microspheres, S. Debono and R. Hamelik for writing the data processing
software, and H. Rickenberg for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Immunoanalysis
Department, Immunotech, a Beckman-Coulter Company, 130 Avenue de Lattre de Tassigny, B.P. 177, 13276 Marseille Cedex 9, France. Phone: 33 4 91 17 27 00. Fax: 33 4 91 17 27 40. E-mail:
defoort{at}immunotech.fr.
Present address: Ipsogen, Parc Scientifique de Luminy, Case 915, 13288 Marseille Cedex 9, France.
 |
REFERENCES |
| 1.
|
Bej, A. K.,
M. H. Mahbubani,
R. Miller,
J. L. DiCesare,
L. Haff, and R. M. Atlas.
1990.
Multiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water.
Mol. Cell. Probes
4:353-365[CrossRef][Medline].
|
| 2.
|
Bichko, V.,
P. Pushko,
D. Dreilina,
P. Pumpen, and E. Gren.
1985.
Subtype ayw variant of hepatitis B virus. DNA primary structure analysis.
FEBS Lett.
185:208-212[CrossRef][Medline].
|
| 3.
|
DiDomenico, N.,
H. Link,
R. Knobel,
T. Caratsch,
W. Weschler,
Z. G. Loewy, and M. Rosenstraus.
1996.
Cobas AmplicorTM: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR.
Clin. Chem.
42:1915-1923[Abstract/Free Full Text].
|
| 4.
|
Frengen, J.,
T. Lindmo,
E. Paus,
R. Schmid, and K. Nustad.
1995.
Dual analyte assay based on particle types of different size measured by flow cytometry.
J. Immunol. Methods
178:141-151[CrossRef][Medline].
|
| 5.
| Fulwyler, M. J. 1976. Method for detecting
and separating antigens and antibodies in blood or other samples.
British patent 15611042.
|
| 6.
|
Guatelli, J. C.,
T. R. Gingeras, and D. D. Richman.
1989.
Nucleic acid amplification in vitro: detection of sequences with low copy numbers and application to diagnosis of human immunodeficiency virus type 1 infection.
Clin. Microbiol. Rev.
2:217-226[Abstract/Free Full Text].
|
| 7.
|
Hart, C.,
G. Schochetman,
T. Spira,
A. Lifson,
J. Moore,
J. Galphin,
J. Sninsky, and C. Y. Ou.
1988.
Direct detection of HIV RNA expression in seropositive subjects.
Lancet
ii:596-599.
|
| 8.
|
Kato, N.,
M. Hijikata,
Y. Ootsuyama,
M. Nakagawa,
S. Ohkoshi,
T. Sugimura, and K. Shimotohno.
1990.
Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.
Proc. Natl. Acad. Sci. USA
87:9524-9528[Abstract/Free Full Text].
|
| 9.
|
Lehtovaara, P.,
M. Uusi-Oukari,
P. Buchert,
M. Laaksonen,
M. Bengtström, and M. Ranki.
1993.
Quantitative PCR for hepatitis B virus with colorimetric detection.
PCR Methods Appl.
3:169-175[Medline].
|
| 10.
|
Mahony, J. B.
1996.
Multiplex polymerase chain reaction for the diagnosis of sexually transmitted diseases.
Clin. Lab. Med.
16:61-71[Medline].
|
| 11.
|
McHugh, T.,
R. C. Miner,
L. H. Logan, and D. P. Stites.
1988.
Simultaneous detection of antibodies to cytomegalovirus and herpes simplex virus by using flow cytometry and microsphere-based fluorescence immunoassay.
J. Clin. Microbiol.
26:1957-1961[Abstract/Free Full Text].
|
| 12.
|
Mellors, J. W.,
C. R. Rinaldo,
P. Gupta,
R. M. White,
J. A. Todd, and L. A. Kingsley.
1996.
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
Science
272:1167-1170[Abstract].
|
| 13.
|
Muesing, M. A.,
D. H. Smith,
C. D. Cabradilla,
C. V. Benton,
L. A. Lasky, and D. J. Capon.
1985.
Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.
Nature
313:450-458[CrossRef][Medline].
|
| 14.
|
Mulder, J.,
N. McKinney,
C. Christopherson,
J. Sninsky,
L. Greenfield, and S. Kwok.
1994.
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.
J. Clin. Microbiol.
32:292-300[Abstract/Free Full Text].
|
| 15.
|
Schooley, R.
1995.
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.
AIDS
9(Suppl. 2):S15-S9.
|
| 16.
|
Scillian, J. J.,
T. M. McHugh,
M. P. Busch,
M. Tam,
M. J. Fulwyler,
D. Y. Chien, and G. N. Vyas.
1989.
Early detection of antibodies against rDNA-produced HIV proteins with a flow cytometric assay.
Blood
73:2041-2048[Abstract/Free Full Text].
|
| 17.
|
Smith, P. L.,
C. R. WalkerPeach,
R. J. Fulton, and D. B. DuBois.
1998.
A rapid, sensitive, multiplexed assay for detection of viral nucleic acids using the FlowMetrix System.
Clin. Chem.
44:2054-2056[Free Full Text].
|
| 18.
|
Stoeckl, E.,
N. Barrett,
F. X. Heinz,
M. banekovich,
G. Stingl,
K. Guggenberger,
F. Dorner, and C. Kunz.
1989.
Efficiency of the polymerase chain reaction for the detection of human immunodeficiency virus type (HIV-1) DNA in the lymphocytes of infected persons: comparison to antigen-enzyme-linked immunosorbent assay and virus isolation.
J. Med. Virol.
29:249-255[Medline].
|
| 19.
|
Tenorio, A.,
J. E. Echeverria,
I. C. J. M. Echeverria, and E. Tabares.
1993.
Detection and typing of human herpes viruses by multiplex polymerase chain reaction.
J. Virol. Methods
44:261-269[CrossRef][Medline].
|
| 20.
|
Vyas, G. N.,
G. Yang, and E. Murphy.
1994.
Transfusion related transmissible diseases: detection by polymerase chain reaction-amplified genes of the microbial agents.
Transfus. Med. Rev.
8:253-266[Medline].
|
| 21.
|
Yang, G.,
P. P. Ulrich,
R. A. Aiyer,
B. D. Rawal, and G. N. Vyas.
1993.
Detection of hepatitis B virus in plasma using flow cytometric analyses of polymerase chain reaction-amplified DNA incorporating digoxigenin-11-dUTP.
Blood
81:1083-1088[Abstract/Free Full Text].
|
| 22.
|
Young, K. K. Y.,
J. J. Archer,
O. Yokosuka,
M. Omatat, and R. M. Resnick.
1995.
Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: comparison with nested amplification and antibody testing.
J. Clin. Microbiol.
33:654-657[Abstract].
|
| 23.
|
Young, K. K. Y.,
R. M. Resnick, and T. W. Myers.
1993.
Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay.
J. Clin. Microbiol.
31:882-886[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, March 2000, p. 1066-1071, Vol. 38, No. 3
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Waltz, T. L., Marras, S., Rochford, G., Nolan, J., Lee, E., Melegari, M., Pollack, H.
(2005). Development of a Molecular-Beacon Assay To Detect the G1896A Precore Mutation in Hepatitis B Virus-Infected Individuals. J. Clin. Microbiol.
43: 254-258
[Abstract]
[Full Text]
-
Meng, Q., Wong, C., Rangachari, A., Tamatsukuri, S., Sasaki, M., Fiss, E., Cheng, L., Ramankutty, T., Clarke, D., Yawata, H., Sakakura, Y., Hirose, T., Impraim, C.
(2001). Automated Multiplex Assay System for Simultaneous Detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human Immunodeficiency Virus Type 1 RNA. J. Clin. Microbiol.
39: 2937-2945
[Abstract]
[Full Text]
-
Camilla, C., Mely, L., Magnan, A., Casano, B., Prato, S., Debono, S., Montero, F., Defoort, J.-P., Martin, M., Fert, V.
(2001). Flow Cytometric Microsphere-Based Immunoassay: Analysis of Secreted Cytokines in Whole-Blood Samples from Asthmatics. CVI
8: 776-784
[Abstract]
[Full Text]